Free Design Audit Available - Click Here for Details

FDA Clears Groundbreaking Corplex P™: The First Human Umbilical Cord-Derived Medical Device

ROSWELL, Ga., Feb. 6, 2024 /PRNewswire/ -- StimLabs® announces FDA 510(k) clearance of Corplex P, the pioneering human umbilical cord-derived medical device. This first-of-its-kind clearance marks a significant milestone for the wound care industry and highlights StimLabs' position at its forefront.

From introducing the first-ever full thickness, intact placental membrane allograft in 2016, to today’s unprecedented 510(k) clearance, StimLabs has consistently set the standard for excellence and innovation in the market. “StimLabs was built as a forward-thinking company, focused on pushing boundaries and driving advancements that redefine standards and progress in healthcare,” says Founder and CEO, John Daniel. “Receiving 510(k) clearance for Corplex P is yet another step in our journey.”

Corplex P is a particulate device derived from human umbilical cord extracellular matrix (ECM) indicated for the management of acute and chronic wounds. Its versatile format, conformability, and retention of ECM components such as collagen and glycosaminoglycans, make it a valuable device in the treating physician’s armamentarium. 

Sign up for Blog Updates